YU13003A - Prolekovi za ligande nmda receptora - Google Patents
Prolekovi za ligande nmda receptoraInfo
- Publication number
- YU13003A YU13003A YU13003A YUP13003A YU13003A YU 13003 A YU13003 A YU 13003A YU 13003 A YU13003 A YU 13003A YU P13003 A YUP13003 A YU P13003A YU 13003 A YU13003 A YU 13003A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- prodrugs
- nmda receptor
- receptor ligands
- compounds
- lower alkyl
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- -1 cyclic tertiary amine Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Pronalazak se odnosi na jedinjenja opšte formule (I) gde R je a) -C(O)(CH2)nC(O)OH, b) gde R1 je -N(R2)(R3) i R2/R3 su nezavisno jedan od drugog vodonik ili niži alkil, ili je ciklični tercijarni amin, proizvoljno supstituisan sa nižim alkilom, c) -P(O)(OH)2 ili je d) -C(O)(CH2)nNHC(O)(CH2)nN(R2)(R3); a ne je 1, 2, 3 ili 4; i na njihove farmaceutski prihvatrljive kisele adicione soli. Ova jedinjenja se mogu koristiti kao prolekovi za matično jedinjenje formule (II) koji su korisni u t retiranju oboljenja povezanih za NMDA-receptorima.[The invention relates to compounds of the general formula (I) wherein R is a) -C(O)(CH2)nC(O)OH, b) wherein R1 is -N(R2)(R3) and R2/R3 are independently from each other hydrogen or lower alkyl, or is a cyclic tertiary amine, optionally substituted by lower alkyl, c) -P(O)(OH)2, or is d) -C(O)(CH)2)nNHC(O)(CH2)nN(R2)(R3); and n is 1, 2, 3 or 4; and to pharmaceutically acceptable acid addition salts thereof. These compounds may be used as prodrugs for the parentcompound of formula (II) which are useful in the treatment of NMDA receptor-related diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00117918 | 2000-08-21 | ||
| PCT/EP2001/009561 WO2002016321A1 (en) | 2000-08-21 | 2001-08-20 | Prodrugs to nmda receptor ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| YU13003A true YU13003A (sh) | 2006-05-25 |
| RS51467B RS51467B (sr) | 2011-04-30 |
Family
ID=8169594
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US6407235B1 (sh) |
| EP (1) | EP1313703B1 (sh) |
| JP (1) | JP4162991B2 (sh) |
| KR (1) | KR100589991B1 (sh) |
| CN (1) | CN1227230C (sh) |
| AR (1) | AR030373A1 (sh) |
| AT (1) | ATE386022T1 (sh) |
| AU (2) | AU2001285894B2 (sh) |
| BR (1) | BR0113348A (sh) |
| CA (1) | CA2419279C (sh) |
| CY (1) | CY1107937T1 (sh) |
| CZ (1) | CZ303319B6 (sh) |
| DE (1) | DE60132782T2 (sh) |
| DK (1) | DK1313703T3 (sh) |
| EC (1) | ECSP034489A (sh) |
| EG (1) | EG24293A (sh) |
| ES (1) | ES2299508T3 (sh) |
| HK (1) | HK1059083A1 (sh) |
| HR (1) | HRP20030125B1 (sh) |
| HU (1) | HU229802B1 (sh) |
| IL (1) | IL154254A0 (sh) |
| JO (1) | JO2289B1 (sh) |
| MA (1) | MA26947A1 (sh) |
| MX (1) | MXPA03001311A (sh) |
| MY (1) | MY136065A (sh) |
| NO (1) | NO324941B1 (sh) |
| NZ (1) | NZ523990A (sh) |
| PA (1) | PA8525601A1 (sh) |
| PE (1) | PE20020291A1 (sh) |
| PL (1) | PL204215B1 (sh) |
| PT (1) | PT1313703E (sh) |
| RS (1) | RS51467B (sh) |
| RU (1) | RU2272027C2 (sh) |
| SI (1) | SI1313703T1 (sh) |
| WO (1) | WO2002016321A1 (sh) |
| ZA (1) | ZA200300894B (sh) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL365444A1 (en) * | 2000-03-21 | 2005-01-10 | The Procter & Gamble Company | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| BRPI0620040A2 (pt) * | 2005-12-19 | 2011-10-25 | Methylgene Inc | inibidores de histona desacetilase para realçar a atividade de agentes antifúngicos |
| US8796330B2 (en) * | 2006-12-19 | 2014-08-05 | Methylgene Inc. | Inhibitors of histone deacetylase and prodrugs thereof |
| KR20090094383A (ko) | 2006-12-19 | 2009-09-04 | 메틸진 인크. | 히스톤 탈아세틸화효소의 억제제 및 이의 프로드럭 |
| PT3066091T (pt) | 2013-11-05 | 2019-07-11 | Astrazeneca Ab | Pro-farmacos de antagonista de nmda |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4410822A1 (de) | 1994-03-24 | 1995-09-28 | Schering Ag | Neue Piperidin-Derivate |
| TW498067B (en) | 1996-07-19 | 2002-08-11 | Hoffmann La Roche | 4-hydroxy-piperidine derivatives |
| TWI254043B (en) | 1999-06-08 | 2006-05-01 | Hoffmann La Roche | Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor |
-
2001
- 2001-08-16 PA PA20018525601A patent/PA8525601A1/es unknown
- 2001-08-16 US US09/931,431 patent/US6407235B1/en not_active Expired - Lifetime
- 2001-08-16 PE PE2001000820A patent/PE20020291A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103939A patent/AR030373A1/es active IP Right Grant
- 2001-08-17 MY MYPI20013876A patent/MY136065A/en unknown
- 2001-08-19 JO JO2001136A patent/JO2289B1/en active
- 2001-08-20 DE DE60132782T patent/DE60132782T2/de not_active Expired - Lifetime
- 2001-08-20 HU HU0301548A patent/HU229802B1/hu not_active IP Right Cessation
- 2001-08-20 CZ CZ20030492A patent/CZ303319B6/cs not_active IP Right Cessation
- 2001-08-20 ES ES01965201T patent/ES2299508T3/es not_active Expired - Lifetime
- 2001-08-20 PL PL361387A patent/PL204215B1/pl unknown
- 2001-08-20 CN CNB01814361XA patent/CN1227230C/zh not_active Expired - Fee Related
- 2001-08-20 RS YUP-130/03A patent/RS51467B/sr unknown
- 2001-08-20 AT AT01965201T patent/ATE386022T1/de active
- 2001-08-20 EP EP01965201A patent/EP1313703B1/en not_active Expired - Lifetime
- 2001-08-20 AU AU2001285894A patent/AU2001285894B2/en not_active Ceased
- 2001-08-20 IL IL15425401A patent/IL154254A0/xx not_active IP Right Cessation
- 2001-08-20 WO PCT/EP2001/009561 patent/WO2002016321A1/en active IP Right Grant
- 2001-08-20 PT PT01965201T patent/PT1313703E/pt unknown
- 2001-08-20 DK DK01965201T patent/DK1313703T3/da active
- 2001-08-20 NZ NZ523990A patent/NZ523990A/en not_active IP Right Cessation
- 2001-08-20 KR KR1020037002485A patent/KR100589991B1/ko not_active IP Right Cessation
- 2001-08-20 RU RU2003107572/04A patent/RU2272027C2/ru not_active IP Right Cessation
- 2001-08-20 AU AU8589401A patent/AU8589401A/xx active Pending
- 2001-08-20 JP JP2002521197A patent/JP4162991B2/ja not_active Expired - Fee Related
- 2001-08-20 MX MXPA03001311A patent/MXPA03001311A/es active IP Right Grant
- 2001-08-20 CA CA002419279A patent/CA2419279C/en not_active Expired - Fee Related
- 2001-08-20 EG EG20010906A patent/EG24293A/xx active
- 2001-08-20 BR BR0113348-9A patent/BR0113348A/pt not_active Application Discontinuation
- 2001-08-20 SI SI200130812T patent/SI1313703T1/sl unknown
-
2003
- 2003-01-31 ZA ZA200300894A patent/ZA200300894B/en unknown
- 2003-02-19 NO NO20030781A patent/NO324941B1/no not_active IP Right Cessation
- 2003-02-20 HR HR20030125A patent/HRP20030125B1/xx not_active IP Right Cessation
- 2003-02-20 EC EC2003004489A patent/ECSP034489A/es unknown
- 2003-02-21 MA MA27052A patent/MA26947A1/fr unknown
-
2004
- 2004-03-16 HK HK04101906A patent/HK1059083A1/xx not_active IP Right Cessation
-
2008
- 2008-05-08 CY CY20081100485T patent/CY1107937T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0104334D0 (sv) | Therapeutic agents | |
| ATE225348T1 (de) | Substituierte azaindolylidenderivate und verfahren zu ihrer herstellung | |
| AU3461697A (en) | Heterocyclic compounds, their production and use | |
| ZA842185B (en) | New n-aryl-n'-cycloalkylalkanoyl-piperazine and process for the production thereof | |
| GB9408185D0 (en) | New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
| ES2187261A1 (es) | Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos. | |
| EP0359276A3 (en) | Stabilized synthetic resin composition | |
| CY1107937T1 (el) | Προφαρμακα σε συνδετες υποδοχεα nmda | |
| IS2472B (is) | Ný tetrahýdrópýridín, framleiðsluaðferð og lyfjasamsetningar sem innihalda þau | |
| FI101301B1 (fi) | Menetelmä terapeuttisesti käyttökelpoisten, N-substituoitujen heksahydroatsepiinijohdannaisten valmistamiseksi | |
| JO2433B1 (en) | Preparation of heterocyclic lindane landscapes | |
| PL362126A1 (en) | New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof | |
| WO2002017954A1 (fr) | Medicaments contre la maladie de parkinson | |
| ATE6500T1 (de) | 2-alpha-methyl-dopaminimino-6,7-dihydroxy-1,2,3 4-tetrahydronaphthalin, seine salze, und verfahren zu dessen herstellung. | |
| IL150100A0 (en) | Pharmaceutical compositions containing fused cyclic compounds | |
| MXPA04002784A (es) | Sales farmaceuticamente aceptables de 20(s)-camptotecinas. | |
| UA42798C2 (uk) | Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, проміжні сполуки, фармацевтична композиція на основі аналогів 15-дезоксипергуаліну | |
| GEP20074217B (en) | Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing | |
| ES8402287A1 (es) | Procedimiento de obtencion de nuevas carboxamidoguanidinas. | |
| IL74877A0 (en) | 9-halogen prostaglandin derivatives,process for the preparation thereof and pharmaceutical compositions containing the same | |
| DE69828037D1 (de) | Pyrroloindol-derivate und zwischenprodukte zu ihrer herstellung | |
| DE502005007939D1 (en) | Enantiomerenreine hexahydropyrrolocyclopentapyridin-derivate |